Tapentadol for neuropathic pain: a review of clinical studies
- PMID: 31190965
- PMCID: PMC6529607
- DOI: 10.2147/JPR.S190162
Tapentadol for neuropathic pain: a review of clinical studies
Abstract
Neuropathic pain (NP) is an enormous burden for patients, caregivers and society. NP is a pain state that may develop after injury of the peripheral or central nervous system because of a wide range of diseases and traumas. A NP symptom component can be found also in several types of chronic pain. Many NP patients are substantially disabled for years. Due to its chronicity, severity and unpredictability, NP is difficult to treat. Tapentadol is a central-acting oral analgesic with combined opioid and noradrenergic properties, which make it potentially suitable for a wide range of pain conditions, particularly whenever a NP component is present or cannot be excluded. In randomized controlled trials, tapentadol has proved to be effective in relieving NP in diabetic peripheral neuropathy and in chronic low back pain. In observational studies, tapentadol reduced NP in chemotherapy-induced peripheral neuropathies, blood and solid cancers, and the NP component in neck pain and Parkinson's disease. This narrative review aims to provide clinicians with a broad overview of tapentadol effects on NP.
Keywords: neuropathic pain; pain therapy; tapentadol.
Conflict of interest statement
UF reports personal fees from Grunenthal, outside the submitted work; HGK has received speaker’s and/or consultancy fees from Bionorica SE, Grunenthal GmbH, Mundipharma Int., TEVA ratiopharm, Mylan, and Pfizer outside the submitted work. HGK reports non-financial support from Grunenthal, during the conduct of the study; personal fees from Bionorica SE, Grunenthal GmbH, Mundipharma Int., TEA ratiopharm, Mylan, Pfizer, outside the submitted work. The authors report no other conflicts on interest in this work.
Figures



Similar articles
-
Tapentadol extended-release for treatment of chronic pain: a review.J Pain Res. 2011;4:211-8. doi: 10.2147/JPR.S14842. Epub 2011 Aug 1. J Pain Res. 2011. PMID: 21887118 Free PMC article.
-
Efficacy of tapentadol ER for managing moderate to severe chronic pain.Pain Physician. 2013 Jan;16(1):27-40. Pain Physician. 2013. PMID: 23340531 Review.
-
Modulation of sensitization processes in the management of pain and the importance of descending pathways: a role for tapentadol?Curr Med Res Opin. 2020 Jun;36(6):1015-1024. doi: 10.1080/03007995.2020.1748876. Epub 2020 Apr 9. Curr Med Res Opin. 2020. PMID: 32216591 Review.
-
Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.Curr Med Res Opin. 2012 Jun;28(6):911-36. doi: 10.1185/03007995.2012.679254. Epub 2012 May 9. Curr Med Res Opin. 2012. PMID: 22443293 Clinical Trial.
-
Modulation of sensitization processes in the management of pain and the importance of descending pathways: a role for tapentadol?Curr Med Res Opin. 2020 May;36(5):I-XVII. doi: 10.1080/03007995.2019.1703664. Curr Med Res Opin. 2020. Retraction in: Curr Med Res Opin. 2020 Mar;36(3):523. doi: 10.1080/03007995.2019.1706283. PMID: 31822137 Retracted.
Cited by
-
Efficacy of Combination Therapy with Pregabalin in Neuropathic Pain: A Preclinical Study in the Rat L5 Spinal Nerve Ligation Model.J Pain Res. 2022 Oct 31;15:3469-3478. doi: 10.2147/JPR.S383981. eCollection 2022. J Pain Res. 2022. PMID: 36338796 Free PMC article.
-
Tapentadol: a new option for the treatment of cancer and noncancer pains.J Pain Res. 2019 May 16;12:1509-1511. doi: 10.2147/JPR.S190171. eCollection 2019. J Pain Res. 2019. PMID: 31190961 Free PMC article. No abstract available.
-
Sex-Gender Differences Are Completely Neglected in Treatments for Neuropathic Pain.Pharmaceuticals (Basel). 2024 Jun 26;17(7):838. doi: 10.3390/ph17070838. Pharmaceuticals (Basel). 2024. PMID: 39065689 Free PMC article. Review.
-
Analgesic and Antidepressant Effects of the Clinical Glutamate Modulators Acetyl-L-Carnitine and Ketamine.Front Neurosci. 2021 May 11;15:584649. doi: 10.3389/fnins.2021.584649. eCollection 2021. Front Neurosci. 2021. PMID: 34045938 Free PMC article. Review.
-
Discovery of RC-752, a Novel Sigma-1 Receptor Antagonist with Antinociceptive Activity: A Promising Tool for Fighting Neuropathic Pain.Pharmaceuticals (Basel). 2023 Jul 5;16(7):962. doi: 10.3390/ph16070962. Pharmaceuticals (Basel). 2023. PMID: 37513874 Free PMC article.
References
-
- Attal N, Bouhassira D. Can pain be more or less neuropathic? Pain. 2004;110:510–511. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous